A study comparing the effectiveness of the drugs Tal-pomalidomide (Tal-P) or Tal-Tec when taken in combination with others to treat blood cancer.

Sponsor: Janssen-Cilag International NV

Cancer type: Relapsed or refractory multiple myeloma

Multiple myeloma is a blood cancer that affects certain types of white blood cells called plasma cells. Although treatments are available, multiple myeloma can come back after treatment or be resistant to standard treatment. Drugs that redirect T cells (a type of white blood cells) to attack cancer cells may be an effective means to destroy cancer cells leading to a long-term treatment response.

In this study, researchers want to learn about effectiveness of the drugs Tal-pomalidomide (Tal-P) or Tal-Tec when taken in combination with others including elotuzumab, pomalidomide, and dexamethasone (EPd) or pomalidomide, bortezomib, and dexamethasone (PVd).

One way to see how well a new treatment works is to measure the time it takes for the disease to come back or get worse. Participants will have an equal chance of receiving either Tal-P or Tal-Tec in addition to EPd or PVd treatment chosen by the study doctor. This is an open-label study, which means that the participant, caregiver, and the study doctor will know about the study drug received.

The trial is also enabling trial patients to access Talquetamab and teclistamab. These are drugs that use modified antibodies to bind with proteins on the surface of multiple myeloma cells and T cells, which activates T cells and kills tumour cells.